All In Biotech

Drug Trial Radar · NCT06028490

A Study of IL4Rα Monoclonal Antibody in Patients With Uncontrolled Seasonal Allergic Rhinitis.

The Efficacy and Safety of IL4Rα Monoclonal Antibody in Patients With Uncontrolled Seasonal Allergic Rhinitis Under Conventional Treatment: A Randomized, Double-Blind, Placebo-controlled Investigator Initiated Trial.

Last checked: Nov 19, 2026Latest source record: Sep 11, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

90

Planned (sponsor's estimate)

Start

Sep 7, 2023

Primary completion

Nov 2023

Study completion Nov 2023

Sponsor

Lead sponsor
Zheng Liu ENTAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 8, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Allergic rhinitis (AR) is a non-infectious chronic inflammatory disease of the nasal mucosa mainly mediated by immunoglobulin E after exposure to allergens in atopic individuals. The typical symptoms of AR are paroxysmal sneezing, watery rhinorrhea, itching, and nasal congestion, which may be accompanied by ocular symptoms, including eye itching, tearing, redness, and burning sensation, which are more common in patients with hay fever allergies. Bronchial asthma is associated with bronchial asthma in 40% of patients with AR, suggesting a comorbid feature of allergic disease.

Conditions

  • Allergic Rhinitis

Interventions

  • GR1802 injection-1Biological

    subcutaneous,dose\*1

  • GR1802 injection-2Biological

    subcutaneous,dose\*2

  • PlaceboBiological

    subcutaneous,dose\*2

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Average change from baseline in daily retrospective total nasal symptom score (rTNSS) during treatment period.Time frame: week 4

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Tongji Hosptial affiliated to Tongji Medical college of Huazhong University of Science and Technology

    Wuhan, Hubei, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.